PD-L1 profiling of circulating tumor cells for immune checkpoint inhibitor therapy in head and neck cancers

被引：0
|
作者：
Patil, Revati [1 ]
Akolkar, Dadasaheb B. [1 ]
Patil, Darshana [1 ]
Devhare, Pradip [1 ]
Srivastava, Navin [1 ]
Fulmali, Pooja [1 ]
Patel, Shoeb [1 ]
Shejwalkar, Pradyumna [1 ]
Datta, Vineet [1 ]
Sims, Cynthe [1 ]
Srinivasan, Ajay [1 ]
Datar, Rajan [1 ]
机构：
[1] Datar Canc Genet Ltd, Nasik, India
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
36
引用
收藏
页数：1
相关论文
共 50 条
  • [21] PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy
    Cottrell, Tricia R.
    Taube, Janis M.
    CANCER JOURNAL, 2018, 24 (01): : 41 - 46
  • [22] Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer
    Kok, Victor C.
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [23] Multimodal detection of PD-L1: reasonable biomarkers for immune checkpoint inhibitor
    Yang, Qiao
    Xu, Zihan
    Zheng, Linpeng
    Zhang, Luping
    You, Qiai
    Sun, Jianguo
    AMERICAN JOURNAL OF CANCER RESEARCH, 2018, 8 (09): : 1689 - 1696
  • [24] Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC
    Kloten, Vera
    Lampignano, Rita
    Krahn, Thomas
    Schlange, Thomas
    CELLS, 2019, 8 (08)
  • [25] Roles of circulating tumor DNA in PD-1/PD-L1 immune checkpoint Inhibitors: Current evidence and future directions
    Liu, Zaoqu
    Han, Yilin
    Dang, Qin
    Xu, Hui
    Zhang, Yuyuan
    Duo, Mengjie
    Lv, Jinxiang
    Li, Huanyun
    Kong, Ying
    Han, Xinwei
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 111
  • [26] Lack of Conventional Acinar Cells in the Salivary Gland Following Anti PD-L1 and anti-PD-1 Immune Checkpoint Inhibitor Therapy
    Pringle, Sarah
    van der Vegt, Bert
    Wang, Xiaoyan
    van Bakelen, Nico
    Vissink, Arjan
    Kroese, Frans
    Bootsma, Hendrika
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [27] PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy
    Dermani, Fatemeh K.
    Samadi, Pouria
    Rahmani, Golebagh
    Kohlan, Alisa K.
    Najafi, Rezvan
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (02) : 1313 - 1325
  • [28] Phytochemicals in regulating PD-1/PD-L1 and immune checkpoint blockade therapy
    Zhang, Qi
    Yang, Chenying
    Gao, Xingsu
    Dong, Ju
    Zhong, Caiyun
    PHYTOTHERAPY RESEARCH, 2024, 38 (02) : 776 - 796
  • [29] Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy
    Song, Yue
    Li, Zhaoming
    Xue, Weili
    Zhang, Mingzhi
    IMMUNOTHERAPY, 2019, 11 (06) : 515 - 529
  • [30] Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients
    Horesh, Adi
    Pollack, Rena
    Nechushtan, Hovav
    Dresner-Pollak, Rivka
    Neuman, Tzahi
    PATHOLOGY & ONCOLOGY RESEARCH, 2023, 29
12345